CareDx Inc (CDNA)
Bid | 14.19 |
Market Cap | 845.51M |
Revenue (ttm) | 346.42M |
Net Income (ttm) | 58.85M |
EPS (ttm) | 0.9 |
PE Ratio (ttm) | 16.87 |
Forward PE | -748.75 |
Analyst | Buy |
Ask | 19.3 |
Volume | 1,248,408 |
Avg. Volume (20D) | 889,401 |
Open | 14.80 |
Previous Close | 15.00 |
Day's Range | 14.63 - 15.41 |
52-Week Range | 9.64 - 34.84 |
Beta | 2.28 |
About CDNA
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The co...
Analyst Forecast
According to 7 analyst ratings, the average rating for CDNA stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 90.98% from the latest price.
Stock ForecastsEarnings Surprise

2 weeks ago · businesswire.com
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ (“CareDx” or the “Company”)— a leading precision medicine company focused on the discovery, development, and co...

1 month ago · businesswire.com
CareDx Launches Two Expanded Indications for AlloSure Testing ServicesBRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...